effects in these populations are unstudied
10,15,65,75 There also are adverse effects on many physiological functions (cardiovascular, bone, immune, brain health, etc.), which are reviewed elsewhere
If these higher-dose arms deliver strong metabolic effects, we could see submissions and real-world use of 2025 mg tirzepatide in T2D patients sometime in late 2026 or 2027
The study protocol was approved by appropriate health authorities according to local guidelines and by the Institutional Review Board/Independent Ethics Committee
Backed by advanced lipos
The information, results, or interpretation of the current study do not represent any opinion of the FDA